Surrozen 過去の業績

過去基準チェック /06

Surrozenの収益は年間平均-4%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間19.1% 52.6%割合で増加しています。

主要情報

-4.0%

収益成長率

26.3%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	52.6%
株主資本利益率	-784.2%
ネット・マージン	-444.4%
前回の決算情報	30 Sep 2024

Recent updates

Here's Why We're A Bit Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Situation

Aug 21

収支内訳

Surrozen の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqCM:SRZN 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
30 Sep 24	10	-44	15	0
30 Jun 24	0	-53	15	-4
31 Mar 24	0	-38	14	0
31 Dec 23	0	-43	16	0
30 Sep 23	13	-35	17	0
30 Jun 23	13	-38	19	14
31 Mar 23	13	-42	20	0
31 Dec 22	13	-36	20	0
30 Sep 22	0	-50	19	0
30 Jun 22	0	-51	17	-19
31 Mar 22	0	-50	15	-9
31 Dec 21	0	-55	14	0
30 Sep 21	0	-51	12	9
30 Jun 21	0	-45	11	34
31 Mar 21	0	-39	10	30
31 Dec 20	0	-33	7	26

質の高い収益: SRZNは現在利益が出ていません。

利益率の向上: SRZNは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: SRZNは利益が出ておらず、過去 5 年間で損失は年間4%の割合で増加しています。

成長の加速: SRZNの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: SRZNは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 16.6% ) と比較することは困難です。

株主資本利益率

高いROE: SRZNは現在利益が出ていないため、自己資本利益率 ( -784.15% ) はマイナスです。

Surrozen 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Recent updates

New major risk - Financial position

Here's Why We're A Bit Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Situation

Price target decreased by 45% to US$33.00

Surrozen, Inc. Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

Surrozen, Inc., Annual General Meeting, Jun 05, 2024

Surrozen, Inc. announced delayed annual 10-K filing

Surrozen Provides Update on the Phase 1A Clinical Trial of SZN-043 in Healthy Volunteers and Patients with Cirrhosis

Surrozen, Inc. announced that it expects to receive $17.549999 million in funding from The Column Group, LLC, Ra Capital Management, Inc.

Surrozen, Inc. Appoints Charles Williams to the Concurrent Position of Chief Operating Officer

Surrozen, Inc. Provides Corporate Update on Clinical Programs

Will Surrozen (NASDAQ:SRZN) Spend Its Cash Wisely?

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Surrozen, Inc. Expects to Initiate A Phase 1a Clinical Trials for SZN-043 and SZN-1326 in Moderate to Severe Alcoholic Hepatitis

New minor risk - Share price stability

Surrozen, Inc. Announces Management Changes

Nasdaq Grants Surrozen Additional 180 Calendar Day Period to Regain Compliance with the Minimum Bid Price Per Share Requirement for Continued Listing

Will Surrozen (NASDAQ:SRZN) Spend Its Cash Wisely?

Here's Why Surrozen (NASDAQ:SRZN) Must Use Its Cash Wisely

Surrozen Receives A Written Notice from Nasdaq Regarding Minimum Bid Requirement

Surrozen, Inc. (NasdaqCM:SRZN) announces an Equity Buyback for 1,310,496 shares, for $2.7 million.

Surrozen, Inc. Updates SZN-1326, SZN-043 and SZN-413 for Vascular-Associated Retinopathies, Including Diabetic Retinopathy and Diabetic Macular Edema

Price target decreased to US$12.50

Surrozen stock rises ~13% premarket on licensing deal with Boehringer Ingelheim

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of Szn-413 in Preclinical Models of Diabetic Retinopathy

Surrozen GAAP EPS of -$0.40 beats by $0.06

Surrozen, Inc. Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

Price target increased to US$19.50

Surrozen, Inc. Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

Surrozen, Inc. Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

Surrozen, Inc. Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

Surrozen, Inc. Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy At the Association for Research in Vision and Ophthalmology Annual Meeting

Surrozen CEO Craig Parker - Biotechs Can Never Be Too Well Capitalized (Video)

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06